dabogratinib
TYRA-300 Small Molecule Target: FGFR3
Tyra Biosciences
Most recent annual filing: 2026-03-02
- BridgeBio infigratinib competitor NDA filing2H 2026BridgeBio infigratinib competitor NDA filing, 2H 2026, notable
- Dabogratinib readout2027Dabogratinib readout, 2027, notable
- BEACH301 ACH readoutlate 1Q 2027BEACH301 ACH readout, late 1Q 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
Technology platforms
SNAP
Proprietary precision medicine platform enabling rapid and precise drug design through iterative molecular SNAPshots using protein crystallography, cell-based assays, and in vivo models. Applied to FGFR biology and other targets for oncology and rare/genetically defined conditions.
Targets: FGFR3, FGFR4, FGFR2, FGFR1, FGFR
Discontinued (1)
- dabogratinib — Metastatic Urothelial Carcinoma · no further development planned due to prioritized focus on more attractive market opportunities
Biotech Distilled coverage (5)
- 2026-09-17 UPDATE: Tyra Biosciences (TYRA) - RA Capital Bought Half the Raise 🔒 Paid
- 2026-09-15 UPDATE: Tyra Biosciences (TYRA) - The Faucet Opened, and the Stock Went Up 🔒 Paid
- 2026-09-09 UPDATE: Tyra Biosciences (TYRA) - The 70% Bar, Missed by Thirteen Points 🔒 Paid
- 2026-08-05 UPDATE: Tyra Biosciences (TYRA) - The Catalyst Slips Again, and the ATM Gets Reloaded 🔒 Paid
- 2026-06-11 Tyra Biosciences (TYRA) — Scientific Deep Dive for Dabogratinib (TYRA-300) and the FGFR Pipeline
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.